Figure 173

At least three growth factors have now been demonstrated to be useful as therapeutic agents in animal models of acute renal failure (ARF). These include epidermal growth factor (EGF), insulin-like growth factor I (IGF-I) and hepatocyte growth factor (HGF). All have efficacy in ischemia models and in a variety of toxic models of ARF. In addition, both IGF-I and HGF are beneficial when therapy is delayed and ARF is "established" after an ischemic insult. IGF-I has the additional advantage in that it also ameliorates the course of renal failure when given prophylactically before an acute ischemic insult.

0 0

Post a comment